İstanbul University İstanbul Faculty of Medicine, Department of Pathology, İstanbul, Türkiye
Koç University Faculty of Medicine, Department of Pathology, İstanbul, Türkiye
Turk J Haematol. 2023 Aug 31;40(3):162-173. doi: 10.4274/tjh.galenos.2023.2023.0110. Epub 2023 Jul 31.
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm.
Sixty-five cases of DLBCL-not otherwise specified, 40 cases of follicular lymphoma (FL), and 19 non-GC-derived lymphoma cases were included in this study. The DLBCL cases were grouped as CD10 (Group A) or only MUM1 (Group B), and the remaining cases constituted the intermediate group (Group C). GCET1, HGAL, and LMO2 expressions were evaluated.
In the FL group, GCET1, HGAL, and LMO2 were positive in 85%, 77.5%, and 100% of the cases, respectively. Among the non-GC-derived lymphoma cases, all three markers were negative in cases of small lymphocytic lymphoma, plasmablastic lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. GCET1 and HGAL were negative in cases of marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Two of the 3 MZL and 2 of the 4 MCL cases were positive for LMO2. In the DLBCL group, the number of cases with GCET1, HGAL, and LMO2 positivity was 18 (90%), 17 (85%), and 20 (100%), respectively, in Group A and 0 (0%), 2 (13.3%), and 2 (13.3%), respectively, in Group B. Considering these rates, when the cases in the intermediate group were evaluated, it was concluded that 13 cases typed as non-GCB according to the Hans algorithm may have the GCB phenotype.
GCET1, HGAL, and LMO2 are highly sensitive markers for determining the germinal center cell phenotype and can increase the accuracy of the subclassification of DLBCL cases, especially for cases that are negative for CD10.
弥漫性大 B 细胞淋巴瘤(DLBCL)是一种具有生物学异质性的疾病,可分为生发中心 B 细胞(GCB)和非 GCB 亚型,这两种亚型具有不同的预后。Hans 算法是最广泛使用的基于 CD10、BCL6 和 MUM1 表达的工具,但已知一些具有非 GCB 表型的病例仍存在分类错误。本研究旨在探讨 GCET1、HGAL 和 LMO2 蛋白表达与 GCB 表型的关系,及其在确定 DLBCL 的 GCB 表型中的作用,以及对 Hans 算法性能的贡献。
本研究纳入了 65 例未特指的 DLBCL 病例、40 例滤泡淋巴瘤(FL)病例和 19 例非 GC 来源的淋巴瘤病例。将 DLBCL 病例分为 CD10 阳性组(A 组)或仅 MUM1 阳性组(B 组),其余病例构成中间组(C 组)。评估 GCET1、HGAL 和 LMO2 的表达。
在 FL 组中,GCET1、HGAL 和 LMO2 在 85%、77.5%和 100%的病例中呈阳性。在非 GC 来源的淋巴瘤病例中,小淋巴细胞淋巴瘤、浆母细胞淋巴瘤、外周 T 细胞淋巴瘤和间变大细胞淋巴瘤的所有 3 种标志物均为阴性。GCET1 和 HGAL 在边缘区淋巴瘤(MZL)和套细胞淋巴瘤(MCL)中为阴性。3 例 MZL 和 4 例 MCL 中有 2 例 LMO2 阳性。在 DLBCL 组中,A 组 GCET1、HGAL 和 LMO2 阳性病例数分别为 18 例(90%)、17 例(85%)和 20 例(100%),B 组分别为 0 例(0%)、2 例(13.3%)和 2 例(13.3%)。考虑到这些比率,当评估中间组病例时,根据 Hans 算法,有 13 例被归类为非 GCB 的病例可能具有 GCB 表型。
GCET1、HGAL 和 LMO2 是确定生发中心细胞表型的高度敏感标志物,可提高 DLBCL 病例亚分类的准确性,特别是对 CD10 阴性的病例。